Barinthus Biotherapeutics plc (NASDAQ: BRNS) announced that its experimental celiac disease treatment VTP-1000 demonstrated a dose-dependent pharmacological effect in the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE